Literature DB >> 17961030

Diagnostic approach to Cushing disease.

Bradley A Gross1, Stefan A Mindea, Anthony J Pick, James P Chandler, H Hunt Batjer.   

Abstract

In Cushing disease, a pituitary corticotroph neoplasm causes secondary adrenal hypercortisolism. This condition has known morbidity and mortality, underscoring the need for an efficient and accurate diagnostic approach. An 11 p.m. salivary cortisol level is a modern, simple initial screening tool for the diagnosis of Cushing syndrome. Confirmation with a 24-hour urinary free cortisol test and/or a low-dose dexamethasone suppression test may subsequently be performed. Patients with repeatedly equivocal results should be reevaluated after several months or undergo a corticotropin-releasing hormone (CRH) stimulation test following low-dose dexamethasone suppression to help rule out pseudo-Cushing states. The presence of low morning serum adrenocorticotropic hormone (ACTH) levels then distinguishes primary adrenal hypercortisolism from Cushing disease and the ectopic ACTH syndrome. Patients with moderate ACTH levels can undergo CRH stimulation testing to clarify the underlying disease because those with an ACTH-independent disorder have blunted subsequent ACTH levels. Once ACTH-dependent hypercortisolemia is detected, magnetic resonance (MR) imaging of the pituitary gland can be performed to detect a pituitary neoplasm. Normal or equivocal MR imaging results revealing small pituitary lesions should be followed up with inferior petrosal sinus sampling, a highly specific measure for the diagnosis of Cushing disease in experienced hands. If necessary, body imaging may be used in turn to detect sources of ectopic ACTH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17961030     DOI: 10.3171/foc.2007.23.3.2

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  7 in total

1.  Assessing the value of bilateral inferior petrosal sinus sampling in the diagnosis and treatment of a complex case of Cushing's disease.

Authors:  Changyan Fan; Chenran Zhang; Xiuhua Shi; Liuguan Bian; Weiguo Zhao; Hua Zhang; Tingwei Su; Weiqing Wang; Xiaoying Li; Guang Ning; Liang Kong; Lingling Hu; Qingfang Sun
Journal:  Intractable Rare Dis Res       Date:  2013-02

2.  Pediatric Cushing's Disease: Dichotomy in Lateralization between Imaging and Inferior Petrosal Sinus Sampling with Review of Literature.

Authors:  Salman Tehran Shaikh; Vikram S Karmarkar; Chandrashekhar Eknath Deopujari
Journal:  J Pediatr Neurosci       Date:  2017 Oct-Dec

Review 3.  Role of Venous Sampling in the Diagnosis of Endocrine Disorders.

Authors:  Ryan W England; Eliza B Geer; Amy R Deipolyi
Journal:  J Clin Med       Date:  2018-05-14       Impact factor: 4.241

4.  Utility of a corticotropin-releasing hormone test to differentiate pituitary-dependent hyperadrenocorticism from cortisol-producing adrenal tumors in dogs.

Authors:  Sachiyo Tanaka; Shuji Suzuki; Asaka Sato; Takahiro Teshima; Akihiro Mori; Toshinori Sako; Aki Tanaka; Yasushi Hara
Journal:  J Vet Intern Med       Date:  2021-12-03       Impact factor: 3.333

5.  Preoperative Diagnosis of Juxtaglomerular Cell Tumors in Eight Patients.

Authors:  Suhai Kang; Fang Chen; Yan Zhong; Baiyu Han; Guanghe Cheng; Aitao Guo; Yuan Tian; Xinyuan Tong; Jingtao Dou; Huiyi Ye
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-03-25       Impact factor: 3.738

6.  Synthesis, biological evaluation and in silico molecular docking of novel 1-hydroxy-naphthyl substituted heterocycles.

Authors:  El-Sayed I El-Desoky; Eman M Keshk; Aya A El-Sawi; Mohamed A Abozeid; Laila A Abouzeid; Abdel-Rahman H Abdel-Rahman
Journal:  Saudi Pharm J       Date:  2018-03-27       Impact factor: 4.330

7.  PREOPERATIVE TREATMENT WITH METYRAPONE IN PATIENTS WITH CUSHING'S SYNDROME DUE TO ADRENAL ADENOMA.

Authors:  Soraya Puglisi; Paola Perotti; Mattia Barbot; Paolo Cosio; Carla Scaroni; Antonio Stigliano; Pina Lardo; Valentina Morelli; Elisa Polledri; Iacopo Chiodini; Giuseppe Reimondo; Anna Pia; Massimo Terzolo
Journal:  Endocr Connect       Date:  2018-09-01       Impact factor: 3.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.